MondegarAI
Euclidean Capital LLC

Q1 2025 · 13F-HR

Euclidean Capital LLCholdings as filed

Filed 2025-05-15 · accession 0001012975-25-000241

$266.1M
Reported value
11
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
46429B598INDAISHARES TR$124.8M46.9%2,425,144CommonSOLE
922042775VEUVANGUARD INTL EQUITY INDEX F$120.8M45.4%1,991,884CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$5.7M2.16%1,573,761CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$5.5M2.07%989,410CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$2.9M1.08%2,627,643CommonSOLE
78462F103SPYSPDR S&P 500 ETF TR$2.3M0.86%4,104CommonSOLE
014442107ALECALECTOR INC$1.6M0.60%1,307,858CommonSOLE
86889P208SRZNSURROZEN INC$1.0M0.38%87,696CommonSOLE
75382E109RAPT THERAPEUTICS INC$802,6370.30%657,899CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$579,0530.22%1,015,705CommonSOLE
86889P117SRZNWSURROZEN INC$5,1250.00%170,833CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.